Status:
TERMINATED
Prevention of Relapses in Proteinase 3 (PR3)-Anti-neutrophil Cytoplasmic Antibodies (ANCA)-Associated Vasculitis
Lead Sponsor:
University Medical Center Groningen
Collaborating Sponsors:
ZonMw: The Netherlands Organisation for Health Research and Development
Dutch Arthritis Association
Conditions:
Vasculitis
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
Treatment of patients with PR3-ANCA-associated vasculitis consists of two phases: remission induction with highly effective, but also relatively toxic, drugs and, secondly, after remission is achieved...
Detailed Description
Treatment of patients with PR3-ANCA-associated vasculitis consists of two phases: remission induction with highly effective, but also relatively toxic, drugs and, secondly, after remission is achieved...
Eligibility Criteria
Inclusion
- Newly diagnosed ANCA-associated vasculitis
- PR3-ANCA antibodies present
- Indication for treatment with cyclophosphamide and prednisolone
Exclusion
- Intolerance or allergy to azathioprine
Key Trial Info
Start Date :
June 1 2003
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2014
Estimated Enrollment :
131 Patients enrolled
Trial Details
Trial ID
NCT00128895
Start Date
June 1 2003
End Date
December 1 2014
Last Update
December 13 2018
Active Locations (8)
Enter a location and click search to find clinical trials sorted by distance.
1
VU University Medical Centre
Amsterdam, Netherlands, 1081HV
2
University Medical Centre Groningen
Groningen, Netherlands, 9700 RB
3
Martini Hospital Groningen
Groningen, Netherlands, 9700RM
4
Medical Centre Leeuwarden
Leeuwarden, Netherlands, 8901BR